Nexstim logo

NEXSTIM TO PRESENT AT ARVOPAPERI’S PROMISING LISTED COMPANIES 2015 INVESTOR EVENT

02 March 2015

Helsinki, 2 March, 2015

Nexstim Oy (“Nexstim” or the “Company”), a medical technology company aiming to improve rehabilitation for stroke patients through the use of non-invasive brain stimulation, announces that it will be presenting at Arvopaperi’s  Promising Listed Companies 2015 investor event at the Crowne Plaza, Helsinki, on 3 March 2015.

Janne Huhtala, Chief Executive Officer, will give a presentation at 9:30am EET on how Nexstim aims to increase the effectiveness of rehabilitation of stroke patients. A copy of the presentation will be available on Nexstim’s website following the event.

Nexstim Plc

Janne Huhtala, Chief Executive Officer

For further information please visit www.nexstim.com or contact:

Nexstim
Janne Huhtala, Chief Executive Officer
janne.huhtala@nexstim.com
+358 (0)40 8615046

UB Capital Oy (Certified Adviser)
+358 (0)9 2538 0225                                             

Consilium Strategic Communications
Mary-Jane Elliott / Ivar Milligan
nexstim@consilium-comms.com
+44 (0)20 3709 5700                                        

About Nexstim Plc

Nexstim, formed in 2000 and based in Finland, is a medical technology company aiming to improve rehabilitation for stroke patients. Nexstim has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) device for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the company has developed a device for stroke therapy called Navigated Brain Therapy (NBT®). In H1 2014, Nexstim initiated a two-year pivotal Phase III study at 12 sites in the US aiming to demonstrate the effectiveness of NBT® and gain FDA clearance for commercialisation in post-acute stroke therapy in the US. Nexstim's shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com.

Back to Press Releases